Bromfenac

Evidence Level: L1

Predicted Indications: 10

Bromfenac

Pharmacist Assessment Report

Bromfenac: From Postoperative Ocular Inflammation to Eye Disease (Dry Eye and VEGF-Driven Maculopathies)

One-Sentence Summary

Bromfenac is a topical non-steroidal anti-inflammatory drug (NSAID) marketed in Canada as an ophthalmic solution, and it is used in the eye for postoperative inflammation and pain. The TxGNN model predicts it may be effective for eye disease (a broad category), with 39 clinical trials and 20 publications linked to this prediction. The most promising specific directions are dry eye disease and macular conditions. The broad “eye disease” label largely overlaps with its established use, so the real repurposing value lies in these sub-indications.

Quick Overview

Item	Content
Original Indication	Not stated in the licence data compiled for this report (the product is an ophthalmic NSAID; postoperative ocular inflammation and pain after cataract surgery is its known use)
Predicted New Indication	Eye disease
TxGNN Prediction Score	0.9980
Evidence Level	L1
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, bromfenac is an NSAID that inhibits cyclooxygenase (COX-1/COX-2) and reduces prostaglandin E2 synthesis. This mechanism is directly relevant to ocular inflammation, post-cataract pain, cystoid macular oedema, and ocular surface inflammation.

Because bromfenac is already used as an ophthalmic solution for postoperative inflammation, “eye disease” is mostly a broad umbrella over established use. The repurposing value lies in more specific sub-indications:

Dry eye disease: supported by a completed Phase 3 dose-ranging trial and a clinical study in patients not controlled by artificial tears.
VEGF-driven maculopathies (neovascular AMD, diabetic macular oedema, retinal vein occlusion): a 2024 review and meta-analysis supports topical bromfenac as an add-on to anti-VEGF injections, and small studies exist for AMD and diabetic macular oedema.

The other predictions are much weaker. Optic papillitis has only an indirect link (topical bromfenac has limited posterior segment penetration). The remaining predictions have no supporting trials or are not mechanistically plausible (for example, von Hippel anomaly, seborrheic keratosis, luxation of globe, lagophthalmos). The literature counts for some of them reflect retrieval artifacts rather than real evidence.

Clinical Trial Evidence

The table lists the most relevant trials among the 39 linked to the “eye disease” prediction.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01212471	Phase 3	Completed	840	Dose-ranging safety and efficacy of bromfenac ophthalmic solution in dry eye disease (strongest direct evidence)
NCT00198445	Phase 3	Completed	527	Bromfenac vs placebo for ocular inflammation after cataract surgery
NCT01774474	Phase 3	Completed	1127	Large RCT on preventing macular oedema after cataract surgery, in patients with and without diabetes
NCT01367249	Phase 3	Completed	440	Bromfenac vs placebo for ocular inflammation and pain after cataract surgery
NCT00704418	Phase 3	Completed	156	Efficacy and safety of bromfenac in cataract surgery
NCT00423007	Phase 3	Completed	90	Bromfenac vs placebo in people with a history of allergic conjunctivitis
NCT00805233	Phase 2	Completed	30	Ranibizumab plus bromfenac vs ranibizumab alone in neovascular AMD (small, combination design)
NCT00758784	Phase 2	Completed	38	Ophthalmic solution in dry eye disease (drug attribution to bromfenac should be verified)
NCT00520260	Phase 4	Completed	42	Bromfenac vs ketorolac during induction of topical cyclosporine in chronic dry eye (comfort outcomes)
NCT07090044	Phase 4	Completed	77	Bromfenac, loteprednol or artificial tears for pain after intravitreal injection

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39180057	2024	Meta-analysis	BMC Ophthalmology	Topical bromfenac as an add-on to anti-VEGF therapy in VEGF-driven maculopathies
25686158	2015	Systematic review	Cochrane Database Syst Rev	Topical NSAIDs for diabetic cystoid macular oedema
39095467	2024	Systematic review / network meta-analysis	Eye (London)	Topical NSAIDs and macular oedema after phacoemulsification
31343372	2019	RCT-based review	Expert Opin Pharmacother	Bromfenac 0.075% in DuraSite for pain and inflammation in cataract surgery
17445902	2007	Clinical trial	Ophthalmology	Bromfenac 0.09% for postoperative ocular pain and inflammation
26068607	2015	Clinical study	Asia Pac J Ophthalmol	Bromfenac in dry eye disease inadequately controlled by artificial tears
37083870	2023	Clinical study	Int Ophthalmol	Topical bromfenac with intravitreal ranibizumab for diabetic macular oedema
19735215	2009	Review	Expert Opin Pharmacother	Twice-daily topical bromfenac; superior to placebo in postoperative inflammation
26502088	2016	Review	Dev Ophthalmol	NSAIDs in the treatment of retinal diseases
38920673	2024	Preclinical (animal)	Cells	Bromfenac reduced neuroinflammation in an ischaemia-reperfusion glaucoma model

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02439123	PROLENSA	Not stated	Not stated
02537788	APO-BROMFENAC	Not stated	Not stated

Safety Considerations

Knowledge-graph contraindication signals (from drug-disease relationships in the TxGNN knowledge graph, not from label text): rheumatoid arthritis, diabetes mellitus, diabetic ketoacidosis. These should be checked against the official product monograph.
Drug interactions: 100 interactions were found. Those listed here are mostly Moderate, with a few Minor. Examples include:
- Corticosteroids: hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide
- Antidiabetic agents: metformin, glimepiride, chlorpropamide
- Aspirin and mesalazine-type agents: acetylsalicylic acid, mesalazine, balsalazide
- Aminoglycosides and glycopeptides: kanamycin, vancomycin
- Bowel preparations and potassium salts
- Minor: cimetidine, linaclotide
Safety signals in the literature: case reports describe corneal melting or perforation (including in Stevens-Johnson syndrome and undiagnosed Sjögren’s syndrome) and toxic epidermal necrolysis after bromfenac eye drops. Systemic bromfenac was withdrawn from the market because of severe liver injury; this concerns the oral form and is not shown for topical use, but it is relevant to risk awareness.

Please refer to the package insert for the official warnings and contraindications.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Phase 3 trials are completed in dry eye disease and in postoperative ocular inflammation, and a recent meta-analysis supports use in maculopathies. However, “eye disease” is a very broad prediction that largely overlaps with the existing approved use, and the other nine predictions (for example optic papillitis and the rare or unrelated conditions) have little or no support and should stay on Hold.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Approved indication text and dosage forms for the two Canadian licences
Mechanism of action data from DrugBank
A narrower target indication (for example dry eye disease or add-on therapy in diabetic macular oedema) with confirmed drug attribution for the ambiguous trials
A monitoring plan for corneal adverse events in patients with ocular surface disease or dry eye, and a review of the interactions listed above
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.